JP2016514114A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016514114A5 JP2016514114A5 JP2015561981A JP2015561981A JP2016514114A5 JP 2016514114 A5 JP2016514114 A5 JP 2016514114A5 JP 2015561981 A JP2015561981 A JP 2015561981A JP 2015561981 A JP2015561981 A JP 2015561981A JP 2016514114 A5 JP2016514114 A5 JP 2016514114A5
- Authority
- JP
- Japan
- Prior art keywords
- administration
- mva
- tcid
- pharmaceutical composition
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000001681 protective effect Effects 0.000 claims description 51
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 42
- 230000004044 response Effects 0.000 claims description 42
- 239000008194 pharmaceutical composition Substances 0.000 claims description 32
- 230000028993 immune response Effects 0.000 claims description 26
- 239000000427 antigen Substances 0.000 claims description 25
- 102000036639 antigens Human genes 0.000 claims description 25
- 108091007433 antigens Proteins 0.000 claims description 25
- 241000700647 Variola virus Species 0.000 claims description 14
- 241000700605 Viruses Species 0.000 claims description 12
- 230000001939 inductive effect Effects 0.000 claims description 10
- 241000700629 Orthopoxvirus Species 0.000 claims description 9
- 241000700618 Vaccinia virus Species 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 3
- 230000006698 induction Effects 0.000 claims 4
- 208000015181 infectious disease Diseases 0.000 claims 4
- 230000002458 infectious effect Effects 0.000 claims 4
- 241001183012 Modified Vaccinia Ankara virus Species 0.000 claims 3
- 230000036755 cellular response Effects 0.000 claims 2
- 230000007123 defense Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 241000282412 Homo Species 0.000 claims 1
- 241000587120 Vaccinia virus Ankara Species 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 23
- 206010011985 Decubitus ulcer Diseases 0.000 description 6
- 208000004210 Pressure Ulcer Diseases 0.000 description 6
- 239000000203 mixture Substances 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 241000711573 Coronaviridae Species 0.000 description 1
- 241000725619 Dengue virus Species 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 229960002235 anthrax antigen Drugs 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940024231 poxvirus vaccine Drugs 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361788722P | 2013-03-15 | 2013-03-15 | |
| US61/788,722 | 2013-03-15 | ||
| PCT/EP2014/000693 WO2014139687A1 (en) | 2013-03-15 | 2014-03-14 | Single high dose of mva induces a protective immune response in neonates and infants |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016514114A JP2016514114A (ja) | 2016-05-19 |
| JP2016514114A5 true JP2016514114A5 (enExample) | 2018-04-05 |
| JP6480875B2 JP6480875B2 (ja) | 2019-03-13 |
Family
ID=50389388
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015561981A Active JP6480875B2 (ja) | 2013-03-15 | 2014-03-14 | 単一高用量のｍｖａは、新生児及び幼児において防御免疫応答を引き起こす |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9707291B2 (enExample) |
| EP (2) | EP2968524A1 (enExample) |
| JP (1) | JP6480875B2 (enExample) |
| KR (1) | KR102269491B1 (enExample) |
| CN (1) | CN105101993A (enExample) |
| AU (4) | AU2014231229A1 (enExample) |
| BR (1) | BR112015021781A2 (enExample) |
| CA (1) | CA2905569C (enExample) |
| EA (1) | EA034825B1 (enExample) |
| HK (1) | HK1216860A1 (enExample) |
| IL (1) | IL241059B (enExample) |
| MX (1) | MX376293B (enExample) |
| MY (1) | MY175269A (enExample) |
| SG (2) | SG10201707340XA (enExample) |
| UA (1) | UA126785C2 (enExample) |
| WO (1) | WO2014139687A1 (enExample) |
| ZA (1) | ZA201507017B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA034825B1 (ru) * | 2013-03-15 | 2020-03-25 | Бавариан Нордик А/С | Разовые высокие дозы mva индуцируют защитный иммунный ответ у новорожденных и младенцев |
| WO2015136056A1 (en) | 2014-03-12 | 2015-09-17 | Bavarian Nordic A/S | Use of oil and water emulsions for increasing b cell responses with modified vaccinia ankara virus |
| US20230233670A1 (en) * | 2020-06-10 | 2023-07-27 | Bavarian Nordic A/S | A Recombinant Modified Vaccinia Virus (MVA) Vaccine Against Coronavirus Disease |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9117596D0 (en) * | 1991-08-15 | 1991-10-02 | John Gibson Lifting Gear Ltd | Pulling system |
| US5471902A (en) * | 1994-02-22 | 1995-12-05 | Athenry Enterprises Limited | Tuning system for pianos |
| US7628980B2 (en) * | 2000-11-23 | 2009-12-08 | Bavarian Nordic A/S | Modified vaccinia virus ankara for the vaccination of neonates |
| US7445924B2 (en) * | 2000-11-23 | 2008-11-04 | Bavarian Nordic A/S | Modified Vaccinia Ankara virus variant and cultivation method |
| US7097842B2 (en) * | 2000-11-23 | 2006-08-29 | Bavarian Nordic A/S | Modified vaccinia virus ankara for the vaccination of neonates |
| HU230198B1 (hu) * | 2000-11-23 | 2015-10-28 | Bavarian Nordic A/S | Módosított Vacciniavírus Ankara-variáns |
| EP1420822B2 (en) | 2002-04-19 | 2017-07-05 | Bavarian Nordic A/S | Modified vaccinia virus ankara for the vaccination of neonates |
| US7501127B2 (en) * | 2002-05-16 | 2009-03-10 | Bavarian Nordic A/S | Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara |
| CN101128217B (zh) * | 2005-02-23 | 2012-04-25 | 巴法里安诺迪克有限公司 | 改良的痘病毒快速诱导抗痘病毒或其它传染物的免疫力的用途 |
| CA2662730A1 (en) * | 2006-09-08 | 2008-03-13 | Bavarian Nordic A/S | Phenotypic and genotypic differences of mva strains |
| US20110052627A1 (en) * | 2008-06-20 | 2011-03-03 | Paul Chaplin | Recombinant modified vaccinia virus measles vaccine |
| JP2013507107A (ja) * | 2009-10-08 | 2013-03-04 | バヴァリアン・ノルディック・アクティーゼルスカブ | Ｈｉｖに対するヒトにおける広範なｔ細胞応答の生成 |
| US9463238B2 (en) * | 2011-12-09 | 2016-10-11 | Bavarian Nordic A/S | Recombinant poxvirus vector comprising tetanus toxin fragment C |
| US10111946B2 (en) * | 2012-06-22 | 2018-10-30 | Bavarian Nordic A/S | Poxviral vectors for low antibody response after a first priming immunization |
| SI2879702T1 (sl) * | 2012-08-01 | 2020-02-28 | Bavarian Nordic A/S | Cepivo na osnovi rekombinantnega modificiranega virusa vakcinacije Ankara (MVA) proti respiratornemu sincitialnemu virusu (RSV) |
| EA034825B1 (ru) * | 2013-03-15 | 2020-03-25 | Бавариан Нордик А/С | Разовые высокие дозы mva индуцируют защитный иммунный ответ у новорожденных и младенцев |
-
2014
- 2014-03-14 EA EA201591803A patent/EA034825B1/ru not_active IP Right Cessation
- 2014-03-14 UA UAA201509740A patent/UA126785C2/uk unknown
- 2014-03-14 WO PCT/EP2014/000693 patent/WO2014139687A1/en not_active Ceased
- 2014-03-14 KR KR1020157029515A patent/KR102269491B1/ko active Active
- 2014-03-14 JP JP2015561981A patent/JP6480875B2/ja active Active
- 2014-03-14 EP EP14713036.3A patent/EP2968524A1/en not_active Ceased
- 2014-03-14 SG SG10201707340XA patent/SG10201707340XA/en unknown
- 2014-03-14 CN CN201480015857.9A patent/CN105101993A/zh active Pending
- 2014-03-14 HK HK16104937.0A patent/HK1216860A1/zh unknown
- 2014-03-14 BR BR112015021781A patent/BR112015021781A2/pt not_active Application Discontinuation
- 2014-03-14 MX MX2015011388A patent/MX376293B/es active IP Right Grant
- 2014-03-14 MY MYPI2015703045A patent/MY175269A/en unknown
- 2014-03-14 EP EP20163606.5A patent/EP3708187A1/en active Pending
- 2014-03-14 SG SG11201507192SA patent/SG11201507192SA/en unknown
- 2014-03-14 CA CA2905569A patent/CA2905569C/en active Active
- 2014-03-14 US US14/776,881 patent/US9707291B2/en active Active
- 2014-03-14 AU AU2014231229A patent/AU2014231229A1/en not_active Abandoned
-
2015
- 2015-09-02 IL IL241059A patent/IL241059B/en active IP Right Grant
- 2015-09-21 ZA ZA2015/07017A patent/ZA201507017B/en unknown
-
2019
- 2019-02-12 AU AU2019200977A patent/AU2019200977A1/en not_active Abandoned
-
2020
- 2020-10-29 AU AU2020260472A patent/AU2020260472A1/en not_active Abandoned
-
2022
- 2022-09-20 AU AU2022235527A patent/AU2022235527B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1420822T4 (en) | Modified vaccinia virus Ankara for vaccination of newborns | |
| Garcia-Atutxa et al. | Advancements in monkeypox vaccines development: a critical review of emerging technologies | |
| US9173933B2 (en) | Recombinant modified vaccinia virus Ankara influenza vaccine | |
| JP6943908B2 (ja) | 迅速かつ持続的な免疫学的治療法 | |
| EP2094299A1 (en) | Recombinant modified vaccinia virus ankara (mva)-based vaccine for the avian flu | |
| CN109689093B (zh) | 适合于粘膜递送的冷适应的和毒力因子缺失的活减毒疫苗 | |
| AU2022235527B2 (en) | Single high dose of mva induces a protective immune response in neonates and infants | |
| Lambe | Novel viral vectored vaccines for the prevention of influenza | |
| KB et al. | Vaccine and vaccination as a part of human life: in view of Covid‐19 | |
| WO2022269003A1 (en) | MVA-BASED VACCINE EXPRESSING A PREFUSION-STABILIZED SARS-CoV-2 S PROTEIN | |
| Dawar et al. | Current status of the coronavirus vaccination development: a review | |
| DK2627774T3 (en) | INFLUENZAVACCINE BASED ON RECOMBINANT MODIFIED VACCINIAVIRUS ANKARA (VAT) | |
| Verges | World Vaccine Congress Europe 2017. Barcelona, Spain-October 10-12, 2017 | |
| Knudsen | Alphavirus replicon-based strategies for vaccination | |
| Sulashvili et al. | THE SCIENTIFIC DISCUSSION OF THE ISSUE AND POSSIBILITIES OF COVID-19 VACCINES ELABORATION PROPOSITIONS FOR PRECLUSION OF THE CORONAVIRUS INFECTION DISEASES IN THE WORLD | |
| NZ711569B2 (en) | Single high dose of mva induces a protective immune response in neonates and infants |